Exelixis(EXEL) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian@exelixis.com Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of$478.1 million - - GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of$0.47 - - Increasing Total Revenues and Net Product Revenue ...